

Spesolimab for hidradenitis suppurativa: A proof-of-concept study

Afsaneh Alavi¹, Errol Prens^{2,3}, Alexa B. Kimball⁴, James G. Krueger⁵, Sutirtha Mukhopadhyay⁶, Hui Wang⁷, Nathalie B. Ivanoff⁶, Ana C. Hernandez Daly⁶, Christos C. Zouboulis^{2,8}


¹Department of Dermatology, Mayo Clinic, Rochester, MN, USA; ²European Hidradenitis Suppurativa Foundation (EHSF) e.V., Dessau, Germany; ³Department of Dermatology, Erasmus University Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA; ⁵Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA; ⁶Boehringer Ingelheim am Rhein, Germany; ⁷Boehringer Ingelheim Shanghai Pharmaceuticals Co Ltd, Shanghai, China; ⁸Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany

Overall, data from this phase IIa PoCC study, and interim analyses from the ongoing OLE study, support the development of spesolimab in HS



INTRODUCTION

- HS is a chronic, debilitating, recurrent inflammatory disorder characterized by painful abscesses, inflammatory nodules, and draining tunnels^{1,2}
- These lesions typically affect inverse body regions with skin folds, such as the axillary, groin, gluteal, and perianal regions
- There is a high unmet need for effective targeted therapies
- The pro-inflammatory IL-36 signaling pathway has been implicated in the HS inflammatory network³
- Spesolimab, an anti–IL-36R monoclonal antibody, selectively inhibits IL-36R signaling and downstream inflammatory pathways



CONCLUSIONS

- In the PoCC study, total counts for all HS lesions decreased over 12 weeks of treatment with spesolimab
- Moreover, a greater proportion of patients in the spesolimab arm experienced a decrease in dT count at Week 12 than in the placebo arm
- The observed decreases in lesion counts and the percentage change in dTs were sustained over 24 weeks of continuous spesolimab treatment
- Similarly, patients treated with spesolimab had a decrease in IHS4 score that was sustained up to Week 24 of continuous spesolimab treatment
- Patients previously randomized to placebo also had a decrease in HS lesion count and IHS4 score at Week 12 of the OLE
- Spesolimab was generally well-tolerated, in line with previous trials in other indications


A, abscess; AE, adverse event; AESI, adverse event of special interest; AN, abscess and inflammatory nodule; ANdT; abscess, inflammatory nodule and draining tunnel; BMI, body mass index; CI, confidence intervals; DLQI, Dermatology Life Quality Index; dT, draining tunnel; HS, hidradenitis suppurativa; HS-PGA, hidradenitis suppurativa Physician Global Assessment; IHS4, International Hidradenitis Suppurativa Severity 3. Hessam S, et al. Br J Dermatol 2018;178:761–767. Score System; IL-36, interleukin-36; IL-36R, interleukin-36 receptor; IV, intravenous; LS, least squares; MMRM, mixed model repeated measures; OLE, open-label extension; PoCC, proof-of-clinical-concept; REML, restricted maximum likelihood; qw, every week; q2w, every 2 weeks; RCTC, Rheumatology Common Toxicity Criteria; SC, subcutaneous; SD, standard deviation; SE, standard error; TNF- α , tumor necrosis factor alpha; TNFi, tumor necrosis factor inhibitor.

1. Jemec GBE. N Engl J Med 2012;366:158–164. 2. Zouboulis CC, et al. Dermatology 2015;231:184–190.

Presented at: Fall Clinical Dermatology Conference[®] 23, Las Vegas, NV, USA; October 19–22, 2023. Originally presented at: 25th World Congress of Dermatology (WCD), Singapore; July 3–8, 2023.

RESULTS


haracteristic	Baseline PoCC study N=52		Baseline OLE study N=45			Baseline*		Week 12 of OLE		Absolute change from	
	Spesolimab (n=35)	Placebo (n=17)	Spesolimab-to-spesolimab (n=30)	Placebo-to-spesolimab (n=15)		(defined as the last the first dose of				baseline to W	eek 12 of OLE
x, n (%)							(spesonnab)				
Female	21 (60.0)	10 (58.8)	19 (63.3)	8 (53.3)							
Male	14 (40.0)	7 (41.2)	11 (36.7)	7 (46.7)	Measure	Spesolimab-to- spesolimab	Placebo-to- spesolimab	Spesolimab-to- spesolimab	Placebo-to- spesolimab	Spesolimab-to- spesolimab	Placebo-to- spesolimab
je, years, mean (SD)	35.7 (11.3)	34.1 (11.0)	35.5 (10.8)†	35.7 (10.7)†		n=26 (Week 0 of PoCC)	n=13 (Week 0 of OLE)	(24 weeks of treatment)	(12 weeks of treatment)	(24 weeks of treatment)	(12 weeks of treatment)
ll, kg/m², mean (SD)	33.2 (8.2)	30.4 (5.6)	33.4 (8.4)	30.6 (5.7)							
or TNFi treatment, n (%)								n=26	n=13	n=26	n=13
TNFi-failure	10 (28.6)	4 (23.5)	9 (30.0)	3 (20.0)							
NFi-naïve	25 (71.4)	13 (76.5)	21 (70.0)	12 (80.0)							
severity*, n (%)											
vild	0	0	3 (10.0)	2 (13.3)	Abscess count	1 5	Γ. 4	1.0	2.5	0.0	1.0
Noderate	8 (22.9)	2 (11.8)	14 (46.7)	2 (13.3)	Mean	1.5	5.4	1.2	3.5	-0.2	-1.9
Severe	27 (77.1)	15 (88.2)	13 (43.3)	11 (73.3)							
count, mean (SD)	11.6 (9.3)	18.9 (15.7)	7.5 (15.5)	17.7 (23.4)	Inflammatory nodule count						
ammatory nodule count, mean (SD)	9.5 (9.3)	15.6 (12.2)	6.8 (15.4)	11.9 (15.8)	Mean	10.3	10.3	6.3	8.6	-4.1	-1.7
count, mean (SD)	3.6 (4.0)	4.5 (4.6)	2.1 (3.1)	5.9 (6.0)							
severity was based on IHS4 criteria.					dT e e und						
the OLE study, baseline age refers to the mean ag	ge at the beginning of the PoC	CC study.			dT count Mean	3.6	5.4	2.3	4.5	-1.3	-0.9
					Medil	3.0	0.4	2.0	4.0	-1.5	-0.9
Efficacy: Week 12	2 data tron	n PoCC	study		IHS4 score						
					Mean	27.7	42.6	18.0	33.7	-9.8	-8.9
Percentage change			Absolute change from baselir		DLQI score						
total AN count		at Week 12		DLGI SCOLE							



values are included in the summary.

A decrease in all lesion types was observed in the spesolimab arm by Week 12

Efficacy: Week 12 data from PoCC study



A greater proportion of patients in the spesolimab vs the placebo arm had a decrease from baseline in dT at Week 12

Disclosures & Acknowledgments

This study was supported and funded by Boehringer Ingelheim. AA is a consultant for AbbVie, Boehringer Ingelheim, InflaRx, Kymera, Novartis, and UCB, and has received speaker fees from AbbVie, Celgene, ChemoCentryx, Eli Lilly, Galderma, InflaRx, Janssen, LEO Pharma, Novartis, Pfizer, Sandoz, and UCB, and grant support (to Erasmus Medical Center) from AbbVie, Celgene, Center for


Human Drug Research, Novartis, Pfizer, Janssen, and UCB: ABK is a consultant for Bayer, Boehringer Ingelheim, Ventyx Biosciences, MoonLake, Eli Lilly, Concert Pharma, Evommune, Sonoma Bio, and Sanofi; receives fellowship funding from Janssen and UCB; and serves on the Board of Directors for Almirall. JGK declares receiving consultant fees/honoraria from AbbVie, Aclaris Therapeutics, Allergan, Almirall, Amgen, Arena, Aristea, Asana Biosciences, and grant support (to The Rockefeller University) from AbbVie, Akros, Allergan, Alergan, Alergan, Alergan, Alergan, Alergan, Alergan, Alergan, Alergan, Arena, Aristea, Asana Biosciences, and grant support (to The Rockefeller University) from AbbVie, Akros, Allergan, Alergan, Alergan, Alergan, Alergan, Alergan, Boehringer Ingelheim, Bristol Myers Squibb, Escalier Biosciences, and grant support (to The Rockefeller University) from AbbVie, Akros, Allergan, Alergan, Alergan and UCB; has received speaker fees from AbbVie, Almirall, and UCB; is President of the European Academy of Dermatology and Venereology; is Editor of the ALLOCATE skin, and Chair of the EHSF e.V.; and his employer has received disease-relevant grants from AbbVie, Boehringer Ingelheim, InflaRx, Novartis, and UCB for his participation as a clinical investigator. The authors met criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of this poster. Boehringer Ingelheim was given the opportunity to review the poster for medical Journal Editors. Isabella Goldsbrough, PhD, of Hyperion, OPEN Health Communications, provided writing, editorial, and formatting support which was contracted and funded by Boehringer Ingelheim.

*Baseline data are given for the subset of patients with data available at Week 12 (n=26 for prior spesolimab, n=13 for prior placebo). †n=27. Patients in the spesolimab-to-spesolimab arm received spesolimab for 12 weeks in the OLE study; patients in the placebo-to-spesolimab arm received spesolimab for 12 weeks in the OLE study only.


After 24 weeks of continuous spesolimab treatment, sustained decreases from baseline were observed in AN, dT, and IHS4 score

Efficacy: Over 24 weeks of spesolimab treatment

Percentage change from baseline in dT count




Absolute change from baseline in IHS4



Patients in the spesolimab-to-spesolimab arm received spesolimab for 12 weeks in the PoCC study, and a further 12 weeks in the OLE study; patients in the placebo-to-spesolimab arm received pesolimab for 12 weeks in the OLE study only.

Decreases from baseline in dT count and IHS4 score observed in the 12-week PoCC study were sustained over the first 12 weeks of the OLE study



Patients in the spesolimab-to-spesolimab arm received spesolimab for 12 weeks in the PoCC study, and a further 12 weeks in the OLE study; patients in the placebo-to-spesolimab arm received spesolimab for 12 weeks in the OLE study only

Safety profile

	PoCC study	(Week 1–12)	OLE study (Week 12–24)			
AEs up to Week 12, n (%)	Spesolimab (n=36)*	Placebo (n=16)	Spesolimab-to- spesolimab (n=30)	Placebo-to-spesolimab (n=15)		
Any AE	28 (77.8)	14 (87.5)	21 (70.0)	9 (60.0)		
	0	0	1 (3.3)	0		
Serious AEs [‡]	0	1 (6.3)	1 (3.3)	1 (6.7)		
Investigator-defined drug-related AEs [§]	15 (41.7)	3 (18.8)	9 (30.0)	3 (20.0)		
AEs leading to treatment discontinuation	0	1 (6.3)	1 (3.3)	2 (13.3)		
Investigator-defined AESIs	0	0	0	0		
Most common AEs ¹						
Headache	4 (11.1)	3 (18.8)	3 (10.0)	0		
Nasopharyngitis	3 (8.3)	3 (18.8)	1 (3.3)	0		
Nausea	4 (11.1)	0	0	0		
Fatigue	4 (11.1)	0	0	0		
Injection site erythema	4 (11.1)	0	2 (6.7)	0		
Injection site pain	3 (8.3)	1 (6.3)	2 (6.7)	0		
Data cut-off at Week 12 of the OLE trial; Last Patient Com *2 patients received inverted treatment at Week 2; there placebo was reported to have an unrelated event of ac by the investigator. A panel of independent neurologists [§] The higher percentage of drug-related AEs in the spesoli	fore, 36 patients were exposed to spe ute hepatitis C; 1 patient in the OLE stu deemed this as a case of peripheral n	udy was reported to have Guillain-Bar europathy. A causal association with	ré syndrome by the investigator and v spesolimab was assessed to be unlike	was assessed as causally related		

Decreases in dT count and IHS4 score were observed in patients after switching from placebo to spesolimab

Spesolimab had a favorable safety profile, and was in line with previous trials



Scan this QR code or visit the URL for a device-friendly version of the original presentation from WCD 2023 nttps://bit.lv/40wa1kb

Click the icon to access an interactive microsite for the original presentatio

